background Dimethylarginine dimethylaminohydrolases 1 (DDAH1) is the major enzyme responsible for inactivation of asymmetric dimethylarginine (ADMA). This study seeks to clarify the correlations between mRNA expression levels of DDAH1 transcript variants and the relationship with ADMA metabolizing activity in human.
Nitric oxide (NO) is an important signaling molecule playing crucial roles in maintaining vascular endothelial function and cardiovascular homeostasis. It exerts cardiovascular protective effects through direct vasodilation, preventing vascular smooth muscle cell proliferation, inhibiting platelet aggregation and adhesion, and inhibiting infiltration of inflammatory cells. 1 NO is synthesized by NO synthase (NOS) from L-arginine in the body. Asymmetric dimethylarginine (ADMA) is an endogenous NOS inhibitor generated by type 1 protein arginine methyltransferase. [2] [3] [4] [5] ADMA plays an important role in the development of cardiovascular diseases such as pulmonary arterial hypertension, 6 hyperhomocysteinemia, 7 coronary heart disease, 8 atherosclerosis, 9 stroke, 10 and renal diseases. 11, 12 Increase in plasma ADMA level is regarded as a novel independent risk factor for cardiovascular diseases, especially for thrombotic diseases such as acute coronary syndrome and stoke. 13, 14 The majority of ADMA formed in the body is hydrolyzed to citrulline and dimethylamine by dimethylarginine dimethylaminohydrolases (DDAHs), 15 and <20% of total ADMA is excreted directly in the urine. 16 Two types of DDAHs, namely DDAH1 and DDAH2, are identified in several species. 17 DDAH1 is expressed in the central nervous system accompanied by neuronal NOS and in vascular endothelial cells in tissues and organs such as the lung, kidney, liver, and skeletal muscle, 18 whereas DDAH2 is expressed predominantly in tissues expressing endothelial NOS, such as the heart, kidney, cytoplasmic vesicles, endothelial cells, and vascular smooth muscle cells. 17, 19 Nonetheless, DDAH1 is the major enzyme responsible for the clearance of circulating ADMA, 19, 20 whereas DDAH2 is important in the regulation of endothelium dependent relaxing factor-induced vasodilatation. 19 Evidence has shown that inhibition of DDAH1 expression results in increased ADMA levels and decreased tube formation ability of the human umbilical vein endothelial cells (HUVECs). 21 On the contrary, overexpression of human DDAH1 in hDDAH1 transgenic mice can reduce ADMA production and counteract the inhibitory effects of ADMA on NO synthesis and angiogenesis. [22] [23] [24] [25] Two human DDAH1 transcript variants could be observed in the National Center of Biotechnology Information database. Transcript variant 1 (NM_012137.3, DDAH1-V1, 3991 bp in length) shows a long coding sequence coding the full-length DDAH1 protein. Transcript variant 2 (NM_001134445.1, DDAH1-V2, 4023 bp in length) shows a shorter coding sequence coding for a truncated protein. It is observed that the residues Cys273, His172, and Asp126 in the full-length DDAH1 protein are indispensable for the catalytic triad for ADMA metabolism. 26, 27 However, it is not known whether the 2 transcript variants contribute equally to ADMA metabolism, and the relationship between the expression levels of these transcripts also remains unknown.
Therefore, we aimed to investigate the correlations between the expression levels of DDAH1 transcript variants in healthy control subjects and in patients suffering from either acute ischemic stroke (AIS) or acute myocardial infarction (AMI), 2 diseases that show increased ADMA levels. Relationship between DDAH1 transcript variants and ADMA metabolism was also analyzed in primarily cultured HUVECs from healthy newborns.
METHODS

Study subjects and isolation of peripheral blood mononuclear cells
Thirty-five patients suffering from AIS, 30 patients suffering from AMI, and 36 healthy control subjects were recruited from Xiangya Hospital, Cental South University between November 2011 and April 2013 in Changsha, Hunan province, P.R. China. Table 1 shows the general characteristics of the subjects. All subjects were residents in Changsha or neighboring areas and were informed of the aims and methods of the study. Signed informed consent was obtained from each of the subjects or their family members. Five milliliters of peripheral venous blood were obtained from each subject with EDTA used as the anticoagulant. Blood samples were diluted with an equivalent volume of phosphate-buffered saline. Peripheral blood mononuclear cells (PBMCs) were isolated by centrifuging (400 × g) and layering for 30 minutes at room temperature using equivalent volume of Histopaque-1077 (Sigma-Aldrich, St. Louis, MO). Total RNA samples were extracted with RNAiso Plus reagents (TAKARA Biotechnology, Dalian, China) and stored at −80 °C until analysis. 
Isolation and primary culture of HUVECs
Fresh umbilical cords were collected from newborns in the Maternal and Child Health Hospital of Hunan Province, China, between December 2011 and June 2012. All mothers were healthy and reported no smoking or drinking history or other chronic diseases. Informed consent was obtained from all mothers. The umbilical cords were cut from placenta and placed into sterile phosphate-buffered saline immediately after delivery. HUVECs were isolated and cultured as described previously. 28 In brief, the umbilical vein was filled with 0.25% trypsin and incubated at 37 °C for about 10 minutes. HUVECs were enriched by centrifuging (1,000 × rpm) and cultured in EGM-2 (Lonza, Basel, Switzerland) medium supplemented with 20% fetal bovine serum at 37 °C in humidified atmosphere with 5% carbon dioxide. Cells of the third generation were collected, cellular RNA was extracted, and cells were also lysed by cell lysis.
The study was approved by the ethics committee of the School of Pharmaceutical Sciences, Central South University, and was registered on http://www.chictr.org (registration number: ChiCTR-RCC-12002817 and ChiCTR-OCS-12002819).
Culture of HUVEC-C and HepG2 cell lines
To determine DDAH1 transcript expression in cell lines, the HUVEC-C and HepG2 cell lines were purchased from American Type Culture Collection (Manassas, Virginia, USA). Immortalized human umbilical vein endothelial cells (HUVEC-C) were cultured in low glucose Dulbecco's modified Eagle's medium (1,000 mg/L, because high glucose damages endothelial cells) with 10% fetal bovine serum. HepG2 cells were cultured in high glucose Dulbecco's modified Eagle's medium (4,500 mg/L, needed for rapid metabolism cell lines) with 10% fetal bovine serum. Total RNA samples were extracted.
Semiquantitative real-time polymerase chain reaction
A total of 500 ng of RNA extracted from PBMCs, HUVECs, HUVEC-C, and HepG2 cell lines was used as the template from each sample for reverse-transcription polymerase chain reaction (RT-PCR) to prepare the first-stand of cDNA, using PrimeScript RT reagent Kit (TAKARA Biotechnology). Relative quantitative analysis of the mRNA expression of DDAH1 transcript variants was carried out with ABI 7300 real-time PCR system using SYBR Premix EX Taq system (TAKARA Biotechnology). Primers used to detect the mRNA expression of DDAH1 transcript variants and the endogenous control GAPDH are shown in Table 2 . The amplification system was comprised of a 10 µl volume containing 5 µl SYBR Premix EX Taq, 0.2 µl Rox reference dye, 0.2 µl of each primer (10 µM), 2 µl cDNA, and 2.4 µl double distilled water (ddH 2 O). The PCR conditions were as follows: an initial denaturation at 95 °C for 30 seconds, followed by 40 cycles of 95 °C for 5 seconds and 60 °C for 31 seconds. The DDAH1 mRNA expression was indicated by comparative Ct (2 −ΔΔCt ) with GAPDH mRNA.
Identifying and characterizing novel DDAH1 transcript variant
Gels slices containing the unknown band in agarose electrophoresis analysis of RT-PCR products were obtained. The gel was purified by DNA recovery kit (TAKARA Biotechnology). The purified DNA fragments were dissolved and underwent direct DNA sequencing with the RT-PCR primers from both ends.
ADMA metabolizing activity assay
Cell lysates were prepared from HUVECs using radio immunoprecipitation assay (RIPA) lysis solution with 1 mM phenylmethanesulfonyl fluoride and then centrifuged at 4 °C for 30 minutes. Total protein content was determined with bicinchoninic acid method. ADMA metabolizing activity of the cell lysates was determined according to the method established by Lin et al. 29 To detail, 20 µl cell lysates were added to 2 separate Eppendorf tubes: 30% sulfurosalicylic acid (to terminate ADMA 
DDAH1-V1F
GGAAGGAGGTTGACATGATGA 157
DDAH1-V1R GCACCTCGTTGATTTGTCCT
DDAH1-V2F′
CCGCAGATCAGTCCAAGT 257
DDAH1-V2R′ ATCTCCGCCATCTAAAGT
DDAH1-V2FL-F GTTTGTTTCTGGACTTCAAC 1053
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TATGTGCACAGCCTCTCCAT 246
DDAH1-V2R TTGGCCAAAGTTACCAGAGC
DDAH1-V3F
GCAAATGTTTATGGGTTGACAT 163
DDAH1-V3R GCACCTCGTTGATTTGTCCT
GAPDH-F CTGCACCACCAACTGCTTAG 282
GAPDH-R AGGTCCACCACTGACACGTT metabolism by DDAHs in the lysates) was added into 1 of the tubes immediately after the addition of 10 µl ADMA (Sigma-Aldrich); the other tube was incubated at 37 °C for 2 hours after the addition of 10 µl ADMA, and 30% sulfurosalicylic acid was then added to terminate the reaction. ADMA concentrations in the 2 tubes were measured with enzyme-linked immunosorbent assay kit (Cusabio Biotech, Wuhan, China), the difference in ADMA contents for 2 tubes was calculated indicating ADMA metabolized, and ADMA metabolizing activity was expressed as micromoles per minute per gram protein.
Statistical analysis
Data are shown as mean ± SD. Statistical analysis was carried out by the software SPSS 13.0. Pairwise correlation analysis between DDAH1 transcript variants were analyzed by partial correlation analysis controlled by factors possibly affecting DDAH1 expression including age, sex, positive history of smoking and alcohol use, and history of hypertension and diabetics mellitus (Spss Inc., Chicago, Illinois, USA). Correlation between DDAH1 transcripts expression and ADMA metabolizing activities was performed with Spearman rank correlation analysis. Differences between 2 groups were compared by independent samples t test. P < 0.05 was considered to be statistically significant.
RESULTS
Identification of a novel human DDAH1 transcript variant
To investigate mRNA expression of the two DDAH1 transcript variants in HUVECs and PBMCs, transcript variant-specific RT-PCR primers were designed (Table 2; Figure 1 ). The primers for DDAH1-V1 analysis (DDAH1-V1F and DDAH1-V1R) flanked exon 1 (E1) to exon 3 (E3), whereas primers for DDAH1-V2 analysis (DDAH1-V2F′ and DDAH1-V2R′) flanked exon′ 1 (E′1) to exon 2 (E2) (Figure 1a) . Electrophoresis of the RT-PCR products for DDAH1-V2 variant showed an additional band shorter than the target band (Figure 1b) . This additional band can be observed in cDNA samples from primary HUVECs, PBMCs, HUVEC-C, and HepG2 cells as well (Figure 1b) . Sequencing of the unknown band indicated a novel transcript variant lacked the exon′ 2 (E′2) as compared with the DDAH1-V2 (Supplementary Figure S1) . RT-PCR with primers (DDAH1-V2FL-F and DDAH1-V2FL-R) ( Table 2) that covered the whole DDAH1-V2 coding sequence and the 5′-UTR was further performed, and a slightly shorter PCR product band accompanying the 1053 bp target band was seen (Supplementary Figure S2) . Sequencing of the bands verified the existence of the novel transcript that shared all other 6 exons but E′2 with DDAH1-V2. The novel transcript variant was designated as DDAH1-V3. 
Pair-wise correlations between mRNA levels of DDAH1 transcript variants in HUVECs and PBMCs
Transcripts-specific primers for semiquantitative realtime PCR analysis of DDAH1-V2 and DDAH1-V3 were further designed (Table 2 ). In HUVECs isolated from healthy newborns, DDAH1-V3 mRNA expression correlated positively with both DDAH1-V2 (R = 0.811; P = 0.000008; n = 21) (Figure 2c ) and DDAH1-V1 (R = 0.454; P = 0.04; n = 21) (Figure 2b ) mRNA expression. No significant correlation between DDAH1-V1 and DDAH1-V2 mRNA expression was observed in HUVECs (R = 0.412; P = 0.06; n = 21) (Figure 2a) .
Significant correlation between DDAH1-V2 and DDAH1-V3 mRNA expression was also observed in PBMCs from healthy subjects, as indicated by partial correlation (R = 0.571; P = 0.001; n = 36) (Supplementary Figure S3) . No significant correlations between DDAH1-V1 and DDAH1-V2 (R = 0.137; P = 0.45) or DDAH1-V3 (R = 0.217; P = 0.23) (Supplementary Figure S3) were observed in PBMCs from healthy subjects.
When PBMCs from AIS and AMI patients were analyzed, significant correlations between pair-wise transcript variants were observed in AIS patients (-V1 and -V2: R = 0.700, P = 0.00003; -V1 and -V3: R = 0.457, P = 0.01; -V2 and -V3: R = 0.616, P=0.0005, n = 35) ( Figure 3 ) and AMI patients (-V1 and -V2: R = 0.651, P = 0.001; -V1 and -V3: R = 0.493, P = 0.01; -V2 and -V3: R = 0.544, P=0.006, n = 30) (Supplementary Figure S4) .
Comparison of the expression abundance of the DDAH1 transcript variants in HUVECs and PBMCs
The cycle threshold (CT) values indicative of the relative abundance of DDAH1 transcript variants by real-time PCR analysis were analyzed. In the primarily cultured HUVECs, mean CT values for DDAH1-V1, -V2, and -V3 mRNA expression were 20.5 ± 1.3, 21.9 ± 1.5 and 22.5 ± 2.4, respectively. In PBMCs from healthy subjects, the mean CT values for DDAH1-V1, -V2, and -V3 transcripts were 29.6 ± 1.5, 32.2 ± 2.0 and 29.6 ± 1.7, respectively. For AIS and AMI patients, the corresponding values were 28.7 ± 1.1, 32.2 ± 2.3, and 29.7 ± 1.3 and 28.7 ± 1.5, 32.1 ± 2.3, and 29.3 ± 1.5, respectively. CT values for DDAH1-V1 were significantly lower than those of -V2 and -V3 in both HUVECs and PBMCs regardless of disease status.
ΔCT (CT DDAH1 transcripts − CT GAPDH ) of each transcript variant in PBMCs with different disease statuses were calculated. In comparison with the control subjects, AIS patients showed significantly increased ΔCT values for both DDAH1-V2 and DDAH1-V3 transcripts (P < 0.05 for -V2; P < 0.01 for -V3) (Supplementary Figure S5) . AMI patients also showed marginally increased ΔCT for DDAH1-V2 (P = 0.07) and DDAH1-V3 (P = 0.09) transcripts. ΔCT values of DDAH1-V1 were comparable among the 3 different statuses (Supplementary Figure S5) .
Correlations between DDAH1 transcript variants and ADMA metabolizing activity in HUVECs cell lysates ADMA metabolizing activity of HUVECs from 12 umbilical cords was determined. The mRNA expression level of DDAH1-V1 correlated positively with ADMA metabolizing activity of the cell lysates from the corresponding individuals (R = 0.805; P = 0.002) (Figure 4a ). No significant correlations between either DDAH1-V2 or DDAH1-V3 mRNA expression and ADMA metabolizing activity of the cell lysates was observed (-V2: R = 0.115, P = 0.72; -V3: R = 0.481, P = 0.11) (Figure 4b,c) .
DISCUSSION
In this study, we identified a novel DDAH1-V3 transcript in human. The DDAH1-V3 variant showed slight difference in exon selection with DDAH1-V2. We also observed significantly positive correlations between DDAH1 transcript variants, especially for DDAH1-V2 and -V3, in primarily cultured HUVECs and in PBMCs. In addition, we found that in primarily cultured HUVECs, only DDAH1-V1 expression level correlates significantly with intracellular ADMA metabolizing activity, which may indicate that DDAH1-V1 is the only transcript variant responsible for ADMA degradation. Of the 3 transcript variants identified, DDAH1-V1 has been studied extensively in recent years. 22, 28, [30] [31] [32] [33] The previous studies determined DDAH1 mRNA expression with primers flanking sequences downstream of exon 2 (Supplementary  Table S1 ). However, these amplified regions represent mutual sequences shared by all 3 transcript variants. As observed in our study, mRNA expression of all 3 transcripts showed high abundance in both HUVECs and PBMCs. Although significantly higher CT values indicating lower mRNA abundance were observed for -V2 and -V3 transcripts in primarily cultured HUVECs and in PBMCs, comparable CT values were observed for -V1 and -V3 transcripts in PBMCs from healthy and AIS subjects. Our findings suggest that the utility of transcript-nonspecific primers is inappropriate for analysis of the functional DDAH1-V1 mRNA expression, as reported previously. 28, 32, 33 In our studies, the mRNA expression levels of DDAH1-V2 and DDAH3-V3 transcripts showed the strongest pairwise correlation. The 2 transcript variants shared all exons but exon 2′. Analysis of the chromosomal contig suggests that the gene coding cysteine-rich, angiogenic inducer 61 (CYR61) is a head-to-head gene located 2.4 kb upstream of the -V2 transcript. Though the transcription start sites were not confirmed herein for DDAH1-V2 and DDAH1-V3, it is very likely that these 2 transcripts are controlled by the same promoter. In contrast, the DDAH1-V1 promoter is located about 119 kb downstream. This may explain why mRNA expression of -V2 and -V3 variants showed the strongest correlation in both HUVECs and PBMCs. Because the 3 promoters are separated remotely, the observation of low degree or even lack of correlation between DDAH1-V1 and -V2 or -V3 is reasonable. Small sample size may also account for these negative findings.
PBMCs are used as surrogates to determine in vivo DDAH1 expression in pathophysiological conditions. 34, 35 It is interesting that the degree of correlation between expression levels of DDAH1-V1 and -V2 is increased whereas the correlation between expression levels of DDAH1-V2 and -V3 is decreased in PBMCs from patients with AIS and AMI. The exact reason for this remains unknown. There is the possibility that DDAH1-V1 and -V2 may undergo similar posttranscriptional regulation in disease states such as AIS and AMI. These findings also suggest the need for utility of transcriptsspecific primers when analyzing DDAH1 mRNA expression. Because the major function of DDAH1 is ADMA metabolism, we analyzed the correlations between expression level of DDAH1 transcript variants and ADMA catalyzing activity in primarily cultured HUVECs. Only DDAH1-V1 mRNA expression was observed to correlate positively with ADMA metabolizing activity of the cell lysates. Our findings suggest that the DDAH1-V1 transcript, but not the -V2 or -V3 transcripts, is responsible for ADMA degradation. Of course, our findings need further confirmation in future studies with larger sample size. It is observed that the residues Cys273, His172, and Asp126 in human DDAH1 form the catalytic triad for ADMA metabolism and are critical for DDAH1 function. 26, 27 A truncated protein lacking the first 103 amino acids on the N-terminal is predicted for -V2 and -V3 transcripts (Supplementary Figure S6) . Whether or not this truncation affects ADMA metabolism remains unknown. We observed no correlation between mRNA expression of -V2 and -V3 transcripts with ADMA catalytic activity in HUVECs; this may indicate that the first 103 amino acids are also important for DDAH1 functioning.
There are 2 types of Ddah1 knockout mice established reported previously. 20, 26 One is Ddah1 exon 1 knockout model, and the global homozygous deletion (DDAH1 -/-) is lethal in embryo. 26 The other model is Ddah1 exon 4 deletion. In contrast with the exon 1 knockout mice, Ddah1 exon 4 global knockout mice develop normally, although decreased ADMA metabolism and impaired endothelial sprouting are observed. 20 Different fates of mice in different knockout models indicate other functions of DDAH1 besides ADMA inactivation. This is supported by the findings that DDAH1 modulates endothelial cell proliferation and tube formation and confers tumor phenotype in C6 gliomas cells independent of its ADMA inactivation ability. 21, 36 Both DDAH1-V2 and DDAH1-V3 transcripts skip exon 1 and mimic exon 1 deletion in mice (Supplementary Figure S6) . We suppose that further studies on these newly identified transcript variants might be helpful to understand additional functions of DDAH1.
In summary, we identified a novel DDAH1 transcript variant DDAH1-V3 and found different degrees of pair-wise correlations between DDAH1 transcripts in HUVECs and in PBMCs from healthy control subjects and patients with acute thrombotic diseases (AIS and AMI). However, only the DDAH1-V1 transcript correlates with ADMA metabolic activity and shows comparable expression under disease status such as AIS and AMI. Our findings suggest utility of transcript variant-specific primers in investigating DDAH1 mRNA expression. The contribution of individual DDAH1 transcripts in ADMA metabolism needs further confirmation with in vitro expressed or purified enzymes. Additional functional studies of the DDAH1-V2 and DDAH1-V3 transcripts and their relevance to DDAH1-related diseases also deserve further study in future.
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